DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months
Elixir Medical Corporation: EuroPCR 2024: Elixir Medical's Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World's First Site-Specific Antithrombotic Therapeutic Compared to DES finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Positive six-month clinical data were announced by Elixir Medical during the Transcatheter Cardiovascular Therapeutics (TCT) conference, TCT 2023, in San Francisco, CA today. The DESyne BDS Plus Randomized Controlled Trial (RCT) evaluated DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES).
Data from a meta-analysis show that a 20% improvement in CV medication adherence could reduce risk for any CV event by 8% and risk for all-cause mortality by 12% among patients with CAD, researchers reported. “Medication adherence has been defined as the extent to which a patient takes medications as prescribed by their health care providers,” Kui Hong, MD, PhD, of the department of